FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer

Overview of attention for article published in Digestive and Liver Disease, May 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Readers on

mendeley: 31 Mendeley

So far, Altmetric has seen 6 X posts from 4 X users, with an upper bound of 3,428 followers.

RT @david_tougeron: A nice trial evaluating SIRT and immune checkpoint inhibitor in metastatic colorectal cancer. FFCD 1709-SIRTCI phase II…

A nice trial evaluating SIRT and immune checkpoint inhibitor in metastatic colorectal cancer. FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in l… https://t.co/AW7JqpypLi

New article: FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer https://t.co/ZaRtmu4hHw #colorectalcancer #oncology https://t.co/DtbVhL4Lrv

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.